Navigation Links
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research

ANN ARBOR, Mich., Nov. 11, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced that the Company's drug candidate, Trimesta™ (oral estriol), will be utilized in a new Phase II clinical trial to evaluate its potential therapeutic effect on cognitive dysfunction observed in female multiple sclerosis (MS) patients. The Skirball Foundation and Adeona have pledged to equally support this clinical trial led by Rhonda Voskuhl, M.D., Director, University of California, Los Angeles (UCLA) Multiple Sclerosis Program, Department of Neurology. The study, which focuses on cognition loss in MS patients, also received contributions from numerous supporters, such as the Sherak Family Fund, the Gustafson Fund, and the Diamont family.

"At some point, 50-65 percent of MS patients will develop problems due to cognitive loss, yet there remains no treatment to target this profound disability. Unfortunately, loss of cognition affects a person's ability to work and is the major reason MS patients stop or decrease their level of work," said Dr. Voskuhl, Principal Investigator. "We are therefore thrilled to begin this novel clinical trial of Trimesta in which the primary endpoint is improvement in cognition and the ultimate goal is to address an unmet need for these patients."

This new randomized, double-blind, placebo-controlled Phase II clinical trial is based on findings from a 10-patient, 22-month, single-agent, crossover clinical trial conducted by Dr. Voskuhl. The results from the crossover trial demonstrated a statistically significant 14% improvement from baseline in Paced Auditory Serial Addition Test (PASAT) cognitive testing scores (p = 0.04) in MS patients after six months of Trimesta therapy. PASAT is a routine cognitive test performed in patients with a wide variety of neuropsychological disorders such as MS.

"We are very pleased to announce the initiation of this new clinical trial that will evaluate our drug candidate Trimesta," said James S. Kuo, M.D., M.B.A., Adeona's CEO and President. "Results from the ongoing Phase II relapsing-remitting MS clinical trial and this new Phase II clinical trial for cognitive dysfunction in MS patients should provide results within the same time frame. Expanding the clinical development of Trimesta in the United States to include cognitive benefit should broaden the potential treatment options for women suffering from MS and should increase the economic opportunity for our drug candidate."

About Trimesta™ (oral estriol)

Trimesta is Adeona's proprietary drug candidate for the treatment of relapsing-remitting MS and for cognitive dysfunction, both in female patients. Estriol has been approved and marketed for more than 40 years throughout Europe and Asia for the treatment of post-menopausal hot flashes. It has never been approved in the United States by the Food and Drug Administration (FDA) for any indication.

On September 19, 2011, Adeona announced that the 150th patient has been enrolled in the randomized, double-blind, placebo-controlled, multi-center clinical trial of its Trimesta drug candidate for relapsing-remitting MS in women, per the original protocol. The Company also announced that Dr. Voskuhl had received funding to continue enrollment of an additional 10-20 patients at all 15 centers.

About Cognitive Dysfunction in Multiple Sclerosis

According to the National Multiple Sclerosis Society and the Multiple Sclerosis Society of Canada publication, Hold that Thought! Cognition and MS, it is fairly common for people with multiple sclerosis to complain of problems remembering things, finding the right words, concentrating on a task or something they are reading, or following a conversation. These are all cognitive symptoms of multiple sclerosis. Fifty to sixty-five percent of those affected by multiple sclerosis have cognitive dysfunction. Despite the fact that most symptoms are mild to moderate, they can have a significant impact on a person's ability to normally function. The overall cognitive dysfunction can be described as a reduction in mental "sharpness."

The major areas of cognition that can be dysfunctional include what are termed complex attention and executive functions. Complex attention involves multitasking, the speed with which information can be processed, learning and memory, and perceptual skills; executive functions include problem solving, organizational skills, the ability to plan, and word finding. Just as the nature, frequency, and severity of multiple sclerosis-related physical problems can widely vary, not all people with multiple sclerosis will display these cognitive issues, and no two people will experience exactly the same types or severity of problems.

About the Phase II Trimesta™ Clinical Trial for Cognitive Dysfunction in Multiple Sclerosis

The randomized, double-blind, placebo-controlled clinical trial of Trimesta is expected to enroll 64 relapsing-remitting or secondary-progressive female MS patients at UCLA. Those between the ages of 18 and 50 will be randomized 1:1 into the treatment and placebo groups. Dr. Voskuhl will administer either oral Trimesta or a matching placebo, in addition to any FDA-approved standard MS treatment. Each patient will be dosed and monitored for one year after being enrolled. The primary endpoint is better cognition scores in the Trimesta group versus the placebo group based on PASAT cognitive testing scores. Detailed information regarding this clinical trial, including contact information for the clinical site, is available at

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company focused on developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Adeona is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company is currently preparing to make the following products commercially available: reaZin™, a medical food for the dietary management of zinc deficiency associated with Alzheimer's disease, and wellZin™, a homeopathic over-the-counter medicine for reducing the duration and symptoms of the common cold. Adeona also operates Adeona Clinical Laboratory, a wholly owned clinical reference laboratory that provides a broad array of chemistry and microbiology diagnostic tests. For more information, please visit Adeona's website at

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the timing of results for the two studies and benefits of expanding the clinical development of Trimesta. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, a failure of the clinical trial to provide desired results, our failure to successfully commercialize a new oral therapy for cognitive dysfunction in  multiple sclerosis and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2010 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Adeona Announces HartLab Expansion Into Microbiology Testing Services
2. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
3. Adeona Announces Second Quarter 2010 Profitability and Achievements
4. Adeona Announces Five Scientific Publications on Role of Copper Toxicity and Zinc Deficiency in Alzheimers Disease and Cognitive Decline
5. Adeona CEO to Provide Keynote Address at the 2010 MichBio Expo & Conference Emerging Biosciences Showcase
6. Adeona to Hold Annual Shareholder Meeting
7. Adeona Announces Third Quarter 2010 Financial Results and Achievements
8. Adeona Acquires Access to Clinical Data Supporting Oral Zinc for Prevention of Infections in the Elderly
9. Adeona to Present at OneMedForum San Francisco 2011 Conference
10. Adeona to Host Investor Day on Zinc Deficiency in Alzheimers Disease
11. Adeona to Raise $4 Million in Registered Direct Offering
Post Your Comments:
(Date:1/16/2017)... PUNE, India , January 16, 2017 /PRNewswire/ ... by Allied Market Research, titled, "Sterilization Technologies Market by ... Forecast, 2014-2022," the global sterilization technologies market is expected ... in 2015, growing at a CAGR of 5.8% from ... dominated the market in 2015, with more than half ...
(Date:1/16/2017)... January 16, 2017 Bill is an internationally ... general management and leadership positions with global medical device companies, including ... track record of launching new products and building successful businesses in ... Africa and North America ... Educated at ...
(Date:1/16/2017)... -- CBDRx, the world,s premiere nutraceutical hemp company, is ... extract to Veteran,s groups across the country. ... to Veteran,s groups across the United States.  Passion is ... world and through their passion, CBDRx honors our Veterans ... hemp extract available. ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Anybody who may be looking for a ... video released by Serenity Recovery, a holistic treatment center for addiction located in Marne, ... footage and testimonials from patients and staff that visited the 2016 Recovery Palooza support ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... Seating. Prairie’s award-winning Reflection® brand of custom seating systems has a well-earned reputation ... Permobil with a platform for innovation and growth in the custom seating business, ...
(Date:1/16/2017)... ... January 16, 2017 , ... St. Louisans are well-aware of the following facts at ... This year’s influenza shot seems to be having no effect on keeping this particularly bad ... of the people around are coughing, sneezing, or sniffling , These facts ...
(Date:1/16/2017)... Pekin, IL (PRWEB) , ... January 16, 2017 ... ... Professionals (iaedp) organized to provide first-quality education and high-level training standards to an ... full spectrum of eating disorder problems. As a way to further its mission ...
(Date:1/16/2017)... ... January 16, 2017 , ... Vixiar ... Officer of the medical device company, effective immediately. , “This is perfect timing ... has a strong track record in medical device market development and revenue growth, ...
Breaking Medicine News(10 mins):